Beckman Symposium Program
Overcoming Resistance to Cancer Immunotherapy
The 28th Beckman Symposium
November 2, 2018
The 28th Beckman Symposium
November 2, 2018
8:30 to 9 a.m.
Registration
Registration
9 to 9:10 a.m. - Welcome
Steven Rosen, M.D.
Provost and Chief Scientific Officer
Director, Comprehensive Cancer Center and
Beckman Research Institute
Irell & Manella Cancer Center Director's Distinguished Chair
SPOC Co-Chairman
Steven Rosen, M.D.
Provost and Chief Scientific Officer
Director, Comprehensive Cancer Center and
Beckman Research Institute
Irell & Manella Cancer Center Director's Distinguished Chair
SPOC Co-Chairman
9:10 to 9:20 a.m. - Overview of Morning Session
Hua Yu, Ph.D.
Billy and Audrey L. Wilder Professor in Tumor Immunotherapy, Associate Chair and Professor, Department of Immuno-Oncology
Hua Yu, Ph.D.
Billy and Audrey L. Wilder Professor in Tumor Immunotherapy, Associate Chair and Professor, Department of Immuno-Oncology
Co-leader, Cancer Immunotherapeutics Program, Comprehensive Cancer Center, City of Hope
Marcin Kortylewski, Ph.D.
Associate Professor
Department of Immuno-Oncology
Beckman Research Institute
City of Hope National Medical Center
Associate Professor
Department of Immuno-Oncology
Beckman Research Institute
City of Hope National Medical Center
9:20 to 10:10 a.m.
Ira Mellman, Ph.D.
Vice President, Cancer Immunology, Genetech
'The mechanistic basis of cancer immunotherapy'
Vice President, Cancer Immunology, Genetech
'The mechanistic basis of cancer immunotherapy'
10:10 to 10:30 a.m. - BREAK
10:30 to 11:20 a.m.
Judith Varner, Ph.D.
Professor, Pathology, University of California San Diego
'Macrophage control of anti-tumor immunity'
Judith Varner, Ph.D.
Professor, Pathology, University of California San Diego
'Macrophage control of anti-tumor immunity'
11:20 a.m. to 12:10 p.m.
Shu-Hsia Chen, Ph.D.
Emily Herrmann Chair in Immunology Research, Cancer Center
Director, Center for Immunotherapy Research
Houston Methodist
'Blocking immunoinhibitory receptor reprograms tumor-associated myeloid cells and promotes antitumor immunity'
Shu-Hsia Chen, Ph.D.
Emily Herrmann Chair in Immunology Research, Cancer Center
Director, Center for Immunotherapy Research
Houston Methodist
'Blocking immunoinhibitory receptor reprograms tumor-associated myeloid cells and promotes antitumor immunity'
12:10 to 1:10 p.m. - LUNCH
1:10 to 1:20 p.m. - Overview of Afternoon Session
Peter Lee, M.D.
Billy Wilder Endowed Professor
Chair, Dept. of Immuno-Oncology
City of Hope Comprehensive Cancer Center
Peter Lee, M.D.
Billy Wilder Endowed Professor
Chair, Dept. of Immuno-Oncology
City of Hope Comprehensive Cancer Center
1:20 to 2:10 p.m.
Sandra Demaria, M.D.
Department of Radiation Oncology and Pathology and laboratory medicine, Weill Cornell Medicine, New York
'Mechanisms regulating the synergy of radiotherapy and immune checkpoint blockade'
2:10 to 2:50 p.m.
Edgar Engleman, M.D.
Professor of Pathology and of Medicine, Standford University
Investigating the basis for efficacy and resistance to tumor immunotherapy
Edgar Engleman, M.D.
Professor of Pathology and of Medicine, Standford University
Investigating the basis for efficacy and resistance to tumor immunotherapy
2:50 to 3:10 - BREAK
3:10 to 4 p.m.
Leonid Metelitsa, M.D.
Professor, Pediatrics-Oncology, Baylor College of Medicine
'Allogeneic NKT cells as a platform for off-the-shelf cancer immunotherapy'
Leonid Metelitsa, M.D.
Professor, Pediatrics-Oncology, Baylor College of Medicine
'Allogeneic NKT cells as a platform for off-the-shelf cancer immunotherapy'
4 to 4:50 p.m.
Hong Qin, Ph.D.
Associate Research Professor
Toni Stephenson Lymphoma Center
Department of Hematology and Hematopoietic Stem Cell Transplantation
City of Hope National Medical Center
'Novel BAFF-R-chimeric antigen receptor T-cell therapy for antigen loss relapsed B-cell tumors'
Hong Qin, Ph.D.
Associate Research Professor
Toni Stephenson Lymphoma Center
Department of Hematology and Hematopoietic Stem Cell Transplantation
City of Hope National Medical Center
'Novel BAFF-R-chimeric antigen receptor T-cell therapy for antigen loss relapsed B-cell tumors'
4:50 to 5 p.m. - Closing Remarks
Larry W. Kwak, M.D.
Vice President and Deputy Director,
Comprehensive Cancer Center
Director, Toni Stephenson Lymphoma Center
Dr. Michael Friedman Professor for Translational Medicine
SPOC Co-Chairman
Larry W. Kwak, M.D.
Vice President and Deputy Director,
Comprehensive Cancer Center
Director, Toni Stephenson Lymphoma Center
Dr. Michael Friedman Professor for Translational Medicine
SPOC Co-Chairman
*Schedule time subject to change